Avapritinib in PDGFRA D842V GIST
This video deals with the mechanism of avapritinib in GIST, current outcomes and challenges with PDGFRA D842V mutated GIST presented by Dr. Sameer Rastogi, All India Institute of Medical Sciences, New Delhi, India..
Breaking News for GIST Patients – Avapritinib Approved!
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Blueprint Medicines Presents Preclinical Data on BLU-285
Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]